7 results
Switching Between Anticoagulants and DOACs
VKA, Dabigatran, Rivaroxaban, Apixaban, Edoxaban, Betrixaban, DOAC, Parenteral anticoagulant

DOI: 10.1161/JAHA.120.017559

#Anticoagulants #DOACs #anticoagulation
Switching Between Anticoagulants ... and DOACs VKA, Dabigatran ... Edoxaban, Betrixaban, DOAC ... #DOACs #anticoagulation ... #Switching #hematology
Anticoagulants Common Reversal Agents
 - Warfarin (Coumadin) → Vitamin K (Phytonadione), 4-factor PCC (Kcentra)
 - Heparin/LMWH
Anticoagulants Common ... Protamine sulfate - Dabigatran ... PCC (Kcentra) #anticoagulation ... #doac #noac #pharmacology ... #hematology #reversal
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Oral anticoagulant ... Clotmaster #VTE #DOAC ... #Anticoagulation ... #Dabigatran #Apixaban ... #Pharmacology #Hematology
DOAC: Cheat Sheet - Atrial Fibrillation, VTE Prophylaxis, VTE and Renal Dosing

Renal Dosing:
Apixaban (25% renal clearance):
patients 5mg bid Dabigatran ... #CheatSheet #Dosing ... OralAnticoagulant #Anticoagulation ... #Hematology #Pharmacology ... #Edoxaban #NOAC
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
direct-acting oral anticoagulants ... direct-acting oral anticoagulant ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology
Effect of Direct Oral Anticoagulants on Hemostatic Tests
Horizontal bars correspond to the approximate range of detectability
of Direct Oral Anticoagulants ... concentrations of dabigatran ... thrombin time #doac ... #noac #anticoagulation ... #hematology #laboratory
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
DOAC, direct oral ... #DOAC #VTE #Malignancy ... Cancer #Algorithm #Anticoagulation ... #Management #Hematology ... #Oncology